Questcor Pharmaceuticals Inc (QCOR): Close To New Highs, Should You Like This Biotech?

Lastly, I really like the company’s recent acquisition of Synacthen. This acquisition removes an overhang that could have been a threat to many of the company’s indications for Acthar. Questcor can now use the two drugs in synergy, marketing the better of the two for specific indications.

With that said, I think Questcor is valued attractively and has already proven itself as a continued growth company. Moreover, the manufacturing process used with Acthar – including spare animal parts and hormones – makes it exceedingly difficult to replicate, and Questcor has not been forthcoming with its manufacturing process. Therefore, Questcor faces no competition, much like Alexion. But it’s still priced very reasonably, unlike Alexion. As a result, with all things considered, I think Questcor should be on you biotech watchlist.

Sherrie Stone has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

The article Close To New Highs, Should You Like This Biotech? originally appeared on Fool.com and is written by Sherrie Stone.

Sherrie is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.